The Tri-Pharma Tournament: Gilead, ViiV, and MSD Battle for the HIV Drug Cup

The Goblet of Fire has been lit, signaling the start of a high-stakes “Tri-Pharma Tournament” in the global HIV market. Three champions—Gilead Sciences, ViiV Healthcare, and Merck (MSD)—have entered the arena to claim the championship cup. For two decades, the standard of care evolved from complex cocktails to convenient Single-Tablet Regimens (STR), significantly boosting patient quality of life. However, as small molecule development nears its limit, the rules of the game have changed. We currently stand at a pivotal turning point where simple viral suppression is no longer the only goal; the race is now decided by who can master the “magic” of reduced dosing frequency and superior adherence.

With the 2024 global HIV drug market exceeding $36 billion, the battleground for 2025 has shifted away from daily pills toward more advanced “spells” : Long-Acting Injectables and next-generation Pre-Exposure Prophylaxis (PrEP). While these three giants currently control the field, the next task in this tournament requires more than just defending territory. It demands innovation that deeply reshapes the patient experience. Below, we analyze the cards each player holds to see who is best positioned to seize the next breakthrough.

Gilead Sciences: Holding the Crown with Capsid Inhibitors

Without doubt that Gilead remains the leader in HIV treatment. Its 2024 HIV product revenue reached $19.6 billion, an 8% year-over-year increase. Their moat is built on continuous innovation in nucleoside reverse transcriptase inhibitors (NRTIs).

Gilead’s Flagship HIV Drugs: Biktarvy and Descovy

Gilead currently relies on two flagship products:

• Biktarvy: This drug generated $13.4 billion in 2024. It grew by 13% annually. It combines a high-barrier integrase inhibitor with TAF. TAF offers better renal and bone safety than older drugs. Biktarvy is the top global choice for new patients.
• Descovy: This drug contributed $2.1 billion in revenue. It dominates the oral PrEP market. Gilead successfully transitioned users from Truvada to Descovy before patent expirations. This preserved their market share and cash flow.

Betting Big on Lenacapavir

Competitors are challenging Gilead’s daily oral dominance. In response, it is betting on a novel mechanism: the capsid inhibitor Lenacapavir (Sunlenca).

Lenacapavir works differently than traditional drugs. It blocks multiple stages of the viral lifecycle. It interferes with nuclear entry, virus assembly, and capsid core formation. This provides a high barrier to resistance.

The drug has shown immense potential:

• Treatment: The CAPELLA trial proved its efficacy in multi-drug resistant patients.
• PrEP: The PURPOSE 1 trial showed 100% efficacy in cisgender women. A simple injection every six months provided full protection.
• Expanded Reach: In September 2024, PURPOSE 2 data showed 96% efficacy in other high-risk groups. This outperforms daily oral Truvada.

ViiV Healthcare Pioneers Long-Acting and Dual Therapies

ViiV Healthcare takes a differentiated approach. They focus on two-drug regimens and long-acting solutions. Their 2024 revenue reached £7.1 billion ($9.2 billion).

Challenging the HIV Treatment Standard with Dovato

Three-drug cocktails have long been the gold standard. ViiV challenges this with Dovato.

Large trials like GEMINI 1 & 2 proved Dovato’s efficacy. It works as well as three-drug regimens for new patients. The goal is to reduce overall drug exposure. This appeals to patients facing lifelong therapy.

Leading Long-Acting Innovation with Cabotegravir

ViiV was the first to commercialize long-acting injectables. Their key asset is the integrase inhibitor Cabotegravir.

• Cabenuva: This is the first complete long-acting HIV treatment. Patients receive injections every one or two months. It solves “pill fatigue” and privacy concerns.
• Apretude: This is the long-acting PrEP version. It requires injections only every two months. Studies show it prevents HIV better than daily pills. This gives ViiV a distinct advantage in the prevention market.

MSD as the Challenger in Ultra-Long-Acting HIV Drug

MSD holds a smaller market share than its rivals. However, their pipeline displays massive ambition. They aim to skip monthly shots and target even longer intervals.

Islatravir and the Annual Implant

MSD is developing Islatravir, a novel NRTTI. It possesses high potency and an incredibly long half-life.

Despite earlier clinical hurdles, development has resumed with adjusted doses. MSD’s boldest plan involves a subcutaneous implant. This device targets a one-year duration for PrEP. If successful, HIV prevention becomes as simple as an annual checkup.

Recent Clinical Wins

MSD announced positive Phase 3 results in late 2025. Their trial (MK-8591A-053) tested a daily dual regimen (doravirine/islatravir).

The results were promising. The efficacy matched Biktarvy in suppressing viral loads. The safety profile was also comparable. This solidifies MSD’s position as a serious contender.

The Final Countdown: Key Factors Determining the Next HIV Market Leader

Long-acting formulations are the future. However, commercialization brings new hurdles. Here are the six decisive factors for the coming years:

1. Convenience: Can dosing frequency decrease further? This directly drives patient adherence.
2. Supply Chain Costs: Injectables require complex cold chains. This tests manufacturing agility and pricing flexibility.
3. Patient Acceptance: Will patients embrace injections or implants? This dictates market penetration rates.
4. Healthcare Burden: Some drugs require clinical administration. This strains medical resources. Subcutaneous options may scale better.
5. Resistance Risks: Missed injections cause low drug tails. This increases resistance risks. Robust tracking systems are essential.
6. Market Access: These drugs carry higher price tags. Insurers must see the value in paying for convenience.

Author

Steven Chung

紅杏枝頭春意鬧固然是眾人所追求的風景，但我願意說，青蘿拂行衣更能湧生感嘆。 願在海量晦澀的生醫資訊中，為您點亮一座心燈塔。鐘煌翔

Related Post

Ranking & Reports

Merck Posts $65B in 2025 Revenue as 80 Phase 3 Programs Advance

2026-02-04

Ranking & Reports

[Illustrations] Global Blockbuster Drug Landscape Shifts in 2026: Keytruda Defends No. 1, “Diabesity” Rivals Surge, IRA Price Caps Take Effect

2026-01-22

Trials & Approvals

Moderna and Merck’s mRNA Cancer Vaccine Cuts Melanoma Recurrence by 49%

2026-01-21